Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).

Stephenson KE, Wegmann F, Tomaka F, Walsh SR, Tan CS, Lavreys L, Ansel JL, Kanjilal DG, Jaegle K, Nkolola JP, Peter L, Fogel R, Bradshaw C, Tyler A, Makoni T, Howe L, Quijada D, Chandrashekar A, Bondzie EA, Borducchi EN, Yanosick KE, Hendriks J, Nijs S, Truyers C, Tolboom J, Zahn RC, Seaman MS, Alter G, Stieh DJ, Pau MG, Schuitemaker H, Barouch DH.

Lancet HIV. 2020 Feb 17. pii: S2352-3018(20)30001-1. doi: 10.1016/S2352-3018(20)30001-1. [Epub ahead of print] Erratum in: Lancet HIV. 2020 Feb 28;:.

PMID:
32078815
2.

Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations.

Salisch NC, Izquierdo Gil A, Czapska-Casey DN, Vorthoren L, Serroyen J, Tolboom J, Saeland E, Schuitemaker H, Zahn RC.

NPJ Vaccines. 2019 Dec 20;4:54. doi: 10.1038/s41541-019-0150-4. eCollection 2019.

3.

Restrained expansion of the recall germinal center response as biomarker of protection for influenza vaccination in mice.

Kil LP, Vaneman J, van der Lubbe JEM, Czapska-Casey D, Tolboom JTBM, Roozendaal R, Zahn RC, Kuipers H, Solforosi L.

PLoS One. 2019 Nov 14;14(11):e0225063. doi: 10.1371/journal.pone.0225063. eCollection 2019.

4.

Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.

van der Lubbe JEM, Verspuij JWA, Huizingh J, Schmit-Tillemans SPR, Tolboom JTBM, Dekking LEHA, Kwaks T, Brandenburg B, Meijberg W, Zahn RC, Roozendaal R, Kuipers H.

Front Immunol. 2018 Oct 12;9:2350. doi: 10.3389/fimmu.2018.02350. eCollection 2018.

5.

Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge.

van der Lubbe JEM, Huizingh J, Verspuij JWA, Tettero L, Schmit-Tillemans SPR, Mooij P, Mortier D, Koopman G, Bogers WMJM, Dekking L, Meijberg W, Kwaks T, Brandenburg B, Tolboom JTBM, Schuitemaker H, Roozendaal R, Kuipers H, Zahn RC.

NPJ Vaccines. 2018 Jul 3;3:25. doi: 10.1038/s41541-018-0063-7. eCollection 2018.

6.

Magnitude and Quality of Cytokine and Chemokine Storm during Acute Infection Distinguish Nonprogressive and Progressive Simian Immunodeficiency Virus Infections of Nonhuman Primates.

Keating SM, Heitman JW, Wu S, Deng X, Stacey AR, Zahn RC, de la Rosa M, Finstad SL, Lifson JD, Piatak M Jr, Gauduin MC, Kessler BM, Ternette N, Carville A, Johnson RP, Desrosiers RC, Letvin NL, Borrow P, Norris PJ, Schmitz JE.

J Virol. 2016 Oct 28;90(22):10339-10350. doi: 10.1128/JVI.01061-16. Print 2016 Nov 15.

7.

A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity.

Brauer F, Schmidt K, Zahn RC, Richter C, Radeke HH, Schmitz JE, von Laer D, Egerer L.

Antimicrob Agents Chemother. 2013 Feb;57(2):679-88. doi: 10.1128/AAC.01152-12. Epub 2012 Nov 12.

8.

Memory CD4(+) T lymphocytes in the gastrointestinal tract are a major source of cell-associated simian immunodeficiency virus in chronic nonpathogenic infection of African green monkeys.

Schmitz JE, Ma ZM, Hagan EA, Wilks AB, Furr KL, Linde CH, Zahn RC, Brenchley JM, Miller CJ, Permar SR.

J Virol. 2012 Oct;86(20):11380-5. Epub 2012 Aug 15.

9.

High cell-free virus load and robust autologous humoral immune responses in breast milk of simian immunodeficiency virus-infected african green monkeys.

Wilks AB, Perry JR, Ehlinger EP, Zahn RC, White R, Gauduin MC, Carville A, Seaman MS, Schmitz JE, Permar SR.

J Virol. 2011 Sep;85(18):9517-26. doi: 10.1128/JVI.00796-11. Epub 2011 Jul 6.

10.

Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease.

Zahn RC, Rett MD, Li M, Tang H, Korioth-Schmitz B, Balachandran H, White R, Pryputniewicz S, Letvin NL, Kaur A, Montefiori DC, Carville A, Hirsch VM, Allan JS, Schmitz JE.

Blood. 2010 Apr 15;115(15):3070-8. doi: 10.1182/blood-2009-10-245225. Epub 2010 Feb 10.

11.

Inhibition of adaptive immune responses leads to a fatal clinical outcome in SIV-infected pigtailed macaques but not vervet African green monkeys.

Schmitz JE, Zahn RC, Brown CR, Rett MD, Li M, Tang H, Pryputniewicz S, Byrum RA, Kaur A, Montefiori DC, Allan JS, Goldstein S, Hirsch VM.

PLoS Pathog. 2009 Dec;5(12):e1000691. doi: 10.1371/journal.ppat.1000691. Epub 2009 Dec 11.

12.

Simian immunodeficiency virus (SIV)-specific CD8+ T-cell responses in vervet African green monkeys chronically infected with SIVagm.

Zahn RC, Rett MD, Korioth-Schmitz B, Sun Y, Buzby AP, Goldstein S, Brown CR, Byrum RA, Freeman GJ, Letvin NL, Hirsch VM, Schmitz JE.

J Virol. 2008 Dec;82(23):11577-88. doi: 10.1128/JVI.01779-08. Epub 2008 Oct 1.

13.

Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.

Zahn RC, Hermann FG, Kim EY, Rett MD, Wolinsky SM, Johnson RP, Villinger F, von Laer D, Schmitz JE.

Gene Ther. 2008 Sep;15(17):1210-22. doi: 10.1038/gt.2008.73. Epub 2008 May 1.

14.

A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus.

Zahn RC, Schelp I, Utermöhlen O, von Laer D.

J Virol. 2007 Jan;81(2):457-64. Epub 2006 Oct 4.

Supplemental Content

Support Center